9.5K views · 734 reactions | Prof William T Abraham from The Ohio State University, US reviews the outcomes from the EMPERIAL trials with a specific focus on the effects of empagliflozin (10mg) on exercise ability, patient-reported outcomes, clinical outcomes and congestion. Supported by an educational grant from the Boehringer Ingelheim & Eli Lilly and Company alliance | Radcliffe Cardiology | Facebook

4.6K views · 151 reactions | Empagliflozin slows the progression of kidney disease in patients with diabetes and albuminuria, but the effects are unclear in patients without diabetes and with low albuminuria levels. New research findings are summarized in a short video. https://nej.md/3GRIbyQ | The New England Journal of Medicine | Facebook